BALAXI PHARMACEUTICALS LIMITED - Asset Resilience Ratio

Latest as of March 2025: 0.42%

BALAXI PHARMACEUTICALS LIMITED (BALAXI) has an Asset Resilience Ratio of 0.42% as of March 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read BALAXI PHARMACEUTICALS LIMITED total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Rs13.04 Million

≈ $140.98K USD Cash + Short-term Investments

Total Assets

Rs3.10 Billion

≈ $33.56 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2025)

This chart shows how BALAXI PHARMACEUTICALS LIMITED's Asset Resilience Ratio has changed over time. See BALAXI PHARMACEUTICALS LIMITED (BALAXI) shareholders funds for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down BALAXI PHARMACEUTICALS LIMITED's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BALAXI PHARMACEUTICALS LIMITED stock valuation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Rs0.00	0%
Short-term Investments	Rs13.04 Million	0.42%
Total Liquid Assets	Rs13.04 Million	0.42%

Asset Resilience Insights

Limited Liquidity: BALAXI PHARMACEUTICALS LIMITED maintains only 0.42% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

BALAXI PHARMACEUTICALS LIMITED Industry Peers by Asset Resilience Ratio

Compare BALAXI PHARMACEUTICALS LIMITED's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Fortress Biotech Inc NASDAQ:FBIO	Biotechnology	11.59%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Apellis Pharmaceuticals Inc NASDAQ:APLS	Biotechnology	0.58%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
BrightGene Bio Medical Technology C SHG:688166	Biotechnology	1.00%
BioArctic AB (publ) ST:BIOA-B	Biotechnology	72.35%
Chengzhi Shareholding Co Ltd SHE:000990	Biotechnology	6.73%

Annual Asset Resilience Ratio for BALAXI PHARMACEUTICALS LIMITED (2013–2025)

The table below shows the annual Asset Resilience Ratio data for BALAXI PHARMACEUTICALS LIMITED.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-03-31	0.42%	Rs13.04 Million ≈ $140.98K	Rs3.10 Billion ≈ $33.56 Million	+0.42pp
2024-03-31	0.00%	Rs1.00K ≈ $10.81	Rs2.58 Billion ≈ $27.94 Million	-4.18pp
2022-03-31	4.18%	Rs73.77 Million ≈ $797.82K	Rs1.76 Billion ≈ $19.08 Million	-6.94pp
2020-03-31	11.12%	Rs40.01 Million ≈ $432.66K	Rs359.71 Million ≈ $3.89 Million	+8.94pp
2019-03-31	2.18%	Rs1.33 Million ≈ $14.38K	Rs61.08 Million ≈ $660.54K	--
2018-03-31	0.00%	Rs0.00 ≈ $0.00	Rs16.87 Million ≈ $182.41K	--
2017-03-31	-0.04%	Rs-11.50K ≈ $-124.37	Rs25.77 Million ≈ $278.65K	-1.27pp
2014-03-31	1.23%	Rs148.09K ≈ $1.60K	Rs12.04 Million ≈ $130.21K	+1.03pp
2013-03-31	0.20%	Rs25.00K ≈ $270.37	Rs12.38 Million ≈ $133.91K	--

pp = percentage points

About BALAXI PHARMACEUTICALS LIMITED

NSE:BALAXI India Biotechnology

Market Cap

$15.90 Million

Rs1.47 Billion INR

Market Cap Rank

#25690 Global

#1432 in India

Share Price

Rs26.63

Change (1 day)

-0.19%

52-Week Range

Rs15.67 - Rs55.98

All Time High

Rs207.74